Literature DB >> 27609731

Endocarditis due to Gemella haemolysans in a newly diagnosed multiple myeloma patient.

Dongyan Liu1, Thomas Bateman2, Elisabeth Carr3, Paul Foster2.   

Abstract

An 87-year-old Caucasian woman with hypertension, diabetes mellitus type 2, and COPD was admitted with 1-week duration of back pain and weight gain. The physical examination revealed jugular venous distention, rales in the left lower lung field, and severe pitting edema over lower extremities. As workup for leukocytosis, blood cultures grew Gemella haemolysans. Subsequently, a transthoracic echocardiogram revealed vegetation on the non-coronary aortic leaflet and mild aortic stenosis. She was treated with ampicillin and gentamicin. After further investigation, the patient was diagnosed with plasma cell myeloma, the monoclonal lambda type. This is the first reported case of G. haemolysans endocarditis in a multiple myeloma patient.

Entities:  

Keywords:  Gemella; Gemella haemolysans; antimicrobial therapy; endocarditis; multiple myeloma

Year:  2016        PMID: 27609731      PMCID: PMC5016745          DOI: 10.3402/jchimp.v6.32357

Source DB:  PubMed          Journal:  J Community Hosp Intern Med Perspect        ISSN: 2000-9666


Infective endocarditis (IE) is mostly caused by Gram-positive bacteria including Staphylococcus and Streptococcus. Gemella haemolysans is a Gram-positive coccoid, catalase-negative, facultative anaerobic microorganism of the mucus membranes in humans. However, G. haemolysans is able to cause severe and generalized infection as opportunistic pathogens, and it has become an emerging bacterial etiology in IE. Generally, Gemella endocarditis is associated with previous valvular damage or a poor dental state. Gemella endocarditis without preexistent valvular pathology has also been reported 1–3. Here, we describe the first case of bacterial endocarditis caused by G. haemolysans in a newly diagnosed multiple myeloma patient.

Case report

An 87-year-old Caucasian female with a history of hypertension, atrial fibrillation (non-valvular) on Coumadin anticoagulation, diabetes mellitus type 2, and COPD was admitted to the hospital with severe back pain, right hip pain, and weight gain over 20 pounds over the past week. Patient also reported constipation due to the use of opiate. She denies fever and chills. On admission, she was afebrile and the physical examination revealed jugular venous distention, few rales in left lower lung field, no wheezing, grade 2 systolic murmur at the aortic area radiating upward, and severe pitting edema over bilateral lower extremities. Laboratory studies disclosed the following data: WBC 8,690/mm3 (10% bands, repeated WBC 11,730), Hb 10.5 g/dL, hematocrit 32.5%, platelet 162,000/mm3, MCV 98, RDW 17.0, sodium 128 mEq/L, Cr 1.5 mg/dL, BUN 39 mg/dL, bicarbonate 21.7 mmol/L, pro BNP 4,841, total protein 10.6 g/dL, and albumin 3.2 g/dL. Chest radiography revealed pulmonary vascular congestion. ABG revealed pH 7.34, pO2 70, pCO2 55, and SaO2 92%. The initial treatment was targeted for heart failure and COPD exacerbation. We treated her with furosemide, short period of prednisone, and tiotropium bromide inhalation. Her hypoxia and edema improved and the Cr improved to 0.6 mg/dL. As workup for leukocytosis, peripheral blood culture grew Gemella haemolysans in two cultures. Subsequently, transthoracic echocardiogram revealed LVEF 60–65%, mild aortic stenosis, and one small vegetation on the non-coronary aortic leaflet (Fig. 1); pulmonary artery pressure was 65 mmHg. We diagnosed infective endocarditis (IE), and we started ampicillin (2 g every 6 h) and gentamicin (100 mg daily, renal dosing) according to the sensitivities. Patient's blood cultures were negative twice before discharge. We continued both ampicillin and gentamicin for 4 weeks from the date of first negative blood culture.
Fig. 1

TTE: a small, mobile 4–5 mm echodensity at the tip of the non-coronary leaflet.

TTE: a small, mobile 4–5 mm echodensity at the tip of the non-coronary leaflet. We performed further investigations for source of infections. MRI of lumbar spine with contrast does not show any evidence of discitis, vertebral osteomyelitis, and epidural abscess, but mild T12 compression fracture. Abdominal and pelvic CT showed colon fecal impaction. Given the patient's age, anemia, back pain, and elevated gamma gap, we have the suspicion of plasma cell disorder. Patient's immunofixation electrophoresis showed an IgG lambda monoclonal protein comprising 39.9% of the total protein, equivalent to 3.8 mg/dL; therefore, we performed bone marrow aspiration and biopsy, which revealed plasma cell myeloma, monoclonal lambda type (35% of the cellular elements). Further skeletal survey did not find any abnormalities except the T12 compression fracture. Head CT showed cortical atrophy, without any bony changes. Patient was discharged with dexamethasone 20 mg weekly and antibiotics. Patient died unexpectedly 1 month later, no autopsy was performed.

Discussion

The members of Gemella species have been classified as G. morbillorum, G. haemolysans, G. bergeri, G. sanguinis, G. palaticanis, and G. cuniculi on the basis of DNA hybridization and comparative 16S rRNA gene sequencing (2). Infections due to G. haemolysans have been reported infrequently. For the first time, Thjotta and Boe described G. haemolysans as Neisseria haemolysans in 1938 (4). Reyn et al. (5) showed that the structure of the cell wall of G. haemolysans was typical of Gram-positive cocci by electron microscopy. The comparative thinness (10–20 nm) of its cell wall accounts for easy decolorization during Gram staining. G. haemolysans may therefore appear as Gram-variable or even Gram-negative. It can be misidentified as a viridians streptococcus or remain unidentified. G. haemolysans often colonizes in the upper respiratory, gastrointestinal, and genitourinary tract as a commensal organism and occasionally causes localized and/or disseminated infections. It is a rare cause of endocarditis, with 19 cases reported in the literature and only four cases associated with prosthetic valve endocarditis (1, 2, 3, 6). Our patient is the second case reported in the United States (7). Most documented cases of G. haemolysans endocarditis occur in patients with underlying mitral or aortic valve disease (including prosthetic valves) and/or poor dentition or dental manipulation, which was not the situation with this patient. Infected valves were aortic and mitral, both of them with the same percentage (50%) (1–3). There are also case reports about meningitis (8) and brain abscess (9). For diagnosing IE, there is generally good agreement between transthoracic echocardiography (TTE) and pathologic findings from autopsy or surgery. However, there are limitations in ultrasound measurements of small vegetations (<3 mm), which might be undetectable by TTE (10). Since our patient's vegetation size was 4–5 mm, and she was fragile, we defer the transesophageal echocardiography. Antimicrobial therapy for G. haemolysans IE would typically include penicillin or ampicillin in combination with gentamicin. In all published cases, patients were successfully treated with antibiotics alone or in combination with cardiac valvular replacement, one patient with prosthetic valve endocarditis requiring implantation of a total artificial heart as a bridge to heart transplantation (6). The results of antimicrobial susceptibility studies by Buu-Hoï A (11) demonstrate that all strains of G. haemolysans were highly sensitive to penicillin G and ampicillin. Their results suggest that penicillin G combined with an aminoglycoside can be recommended for the treatment of endocarditis caused by G. haemolysans. Patients with multiple myeloma are more susceptible to infections, which are the major causes of morbidity and mortality. Despite the common occurrence of bacteremia, IE is seldom reported. By searching PubMed, we can only find scattered case reports without statistic data about IE in multiple myeloma patients.

Conclusion

G. haemolysans is a rare but important cause of IE. The association of G. haemolysans and multiple myeloma has not been reported to date. Patients with multiple myeloma are susceptible to infection due to compromised immunoglobulin synthesis and function. In summary, because of the lack of other risk factors, we felt that multiple myeloma maybe a under recognized risk factor for endocarditis due to G. haemolysans.

Disclosure

None of the authors have any financial or personal bias that would inappropriately compromise the publication of this work.
  10 in total

1.  Endocarditis due to Gemella haemolysans in a patient with hemochromatosis.

Authors:  J D Mosquera; M Zabalza; M Lantero; J R Blanco
Journal:  Clin Microbiol Infect       Date:  2000-10       Impact factor: 8.067

2.  Prosthetic valve endocarditis by Gemella haemolysans.

Authors:  P Morea; M Toni; M Bressan; P Stritoni
Journal:  Infection       Date:  1991 Nov-Dec       Impact factor: 3.553

3.  Meningitis due to Gemella haemolysans after radiofrequency trigeminal rhizotomy.

Authors:  R G Mitchell; P J Teddy
Journal:  J Clin Pathol       Date:  1985-05       Impact factor: 3.411

Review 4.  Subacute endocarditis caused by Gemella haemolysans and a review of the literature.

Authors:  Raymond Khan; Carl Urban; David Rubin; Sorana Segal-Maurer
Journal:  Scand J Infect Dis       Date:  2004

Review 5.  Molecular identification of Gemella species from three patients with endocarditis.

Authors:  B La Scola; D Raoult
Journal:  J Clin Microbiol       Date:  1998-04       Impact factor: 5.948

6.  Two-dimensional echocardiographic assessment of vegetative endocarditis.

Authors:  B W Gilbert; R S Haney; F Crawford; J McClellan; H A Gallis; M L Johnson; J A Kisslo
Journal:  Circulation       Date:  1977-02       Impact factor: 29.690

7.  Brain abscess due to Gemella haemolysans.

Authors:  Mi Ra Lee; Sang-Oh Lee; Sue-Yun Kim; Sun Mee Yang; Yiel-Hae Seo; Yong Kyun Cho
Journal:  J Clin Microbiol       Date:  2004-05       Impact factor: 5.948

8.  Antimicrobial susceptibility of Gemella haemolysans isolated from patients with subacute endocarditis.

Authors:  A Buu-Hoï; A Sapoetra; C Branger; J F Acar
Journal:  Eur J Clin Microbiol       Date:  1982-04       Impact factor: 3.267

9.  Total Artificial Heart as Bridge to Transplantation for Severe Culture-Negative Prosthetic Valve Endocarditis Due to Gemella haemolysans.

Authors:  Meena S Ramchandani; Robert M Rakita; Rosario V Freeman; Wayne C Levy; Peter Von Homeyer; Nahush A Mokadam
Journal:  ASAIO J       Date:  2014 Jul-Aug       Impact factor: 2.872

10.  Fine structure and taxonomic position of Neisseria haemolysans (Thjotta and Boe 1938) or Gemella haemolysans (Berger 1960).

Authors:  A Reyn; A Birch-Andersen; U Berger
Journal:  Acta Pathol Microbiol Scand B Microbiol Immunol       Date:  1970
  10 in total
  6 in total

1.  Investigation of recombination-intense viral groups and their genes in the Earth's virome.

Authors:  Jan P Meier-Kolthoff; Jumpei Uchiyama; Hiroko Yahara; David Paez-Espino; Koji Yahara
Journal:  Sci Rep       Date:  2018-07-31       Impact factor: 4.379

2.  Risk Factors and Patient Profile of Infective Endocarditis due to Gemella spp.

Authors:  Pramod Theetha Kariyanna; Bayu Sutarjono; Naga Pranavi Ellanti; Apoorva Jayarangaiah; Amog Jayarangaiah; Harshith Priyan Chandrakumar; Ashkan Tadayoni; Moro O Salifu; Isabel M McFarlane
Journal:  Am J Med Case Rep       Date:  2020-12-13

3.  A Case Report of Gemella haemolysans Keratitis After Refractive Surgery.

Authors:  Yaohua Zhai; Chenjiu Pang; Shengtao Sun; Qiufei Ma; Lei Han; Yuwei Gu; Lizhe Gu
Journal:  Infect Drug Resist       Date:  2021-12-06       Impact factor: 4.003

4.  Gemella haemolysans as an emerging pathogen for bacteremia among the elderly.

Authors:  Satoko Kodaka; Takuro Uchida; Harumi Gomi
Journal:  J Gen Fam Med       Date:  2021-10-05

5.  A Rare Case of Infective Endocarditis Caused by Gemella haemolysans.

Authors:  Tanushree Agrawal; Malcolm Irani; Stephanie Fuentes Rojas; Omar Jeroudi; Ejaz Janjua
Journal:  Cureus       Date:  2019-11-26

6.  A Rare Case of Gemella haemolysans Infection of Knee Arthroplasty.

Authors:  Kanchi Patell; Abdul Rahman Al Armashi; Francisco J Somoza-Cano; Keyvan Ravakhah; Julia Han
Journal:  Cureus       Date:  2021-08-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.